SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 230 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $7,269,000 | +7.1% | 224,892 | -3.4% | 0.00% | +33.3% |
| Q4 2021 | $6,785,000 | +46.6% | 232,698 | +34.1% | 0.00% | 0.0% |
| Q3 2021 | $4,629,000 | +1.1% | 173,557 | +16.7% | 0.00% | 0.0% |
| Q2 2021 | $4,578,000 | +11.0% | 148,684 | -5.7% | 0.00% | +50.0% |
| Q1 2021 | $4,126,000 | -5.3% | 157,592 | -9.0% | 0.00% | -33.3% |
| Q4 2020 | $4,359,000 | +39.8% | 173,236 | +15.8% | 0.00% | +50.0% |
| Q3 2020 | $3,117,000 | -7.7% | 149,588 | +5.2% | 0.00% | -33.3% |
| Q2 2020 | $3,377,000 | +118.2% | 142,187 | +65.2% | 0.00% | +200.0% |
| Q1 2020 | $1,548,000 | -43.4% | 86,069 | -25.3% | 0.00% | -50.0% |
| Q4 2019 | $2,735,000 | -36.1% | 115,292 | -26.0% | 0.00% | -33.3% |
| Q3 2019 | $4,281,000 | -19.5% | 155,772 | -3.1% | 0.00% | -25.0% |
| Q2 2019 | $5,320,000 | -26.6% | 160,784 | -22.2% | 0.00% | -33.3% |
| Q1 2019 | $7,244,000 | -21.7% | 206,721 | -25.8% | 0.01% | -33.3% |
| Q4 2018 | $9,256,000 | -45.8% | 278,617 | -17.8% | 0.01% | -40.0% |
| Q3 2018 | $17,071,000 | -28.6% | 339,043 | -15.2% | 0.02% | -34.8% |
| Q2 2018 | $23,924,000 | +37.5% | 399,734 | +5.2% | 0.02% | +35.3% |
| Q1 2018 | $17,396,000 | +41.6% | 379,831 | +23.2% | 0.02% | +41.7% |
| Q4 2017 | $12,289,000 | -8.5% | 308,389 | -8.2% | 0.01% | -20.0% |
| Q3 2017 | $13,434,000 | +1.5% | 335,847 | +9.3% | 0.02% | -6.2% |
| Q2 2017 | $13,237,000 | +51.7% | 307,131 | +10.2% | 0.02% | +23.1% |
| Q1 2017 | $8,723,000 | +36.9% | 278,685 | +10.5% | 0.01% | +44.4% |
| Q4 2016 | $6,370,000 | +17.3% | 252,268 | +14.9% | 0.01% | +12.5% |
| Q3 2016 | $5,432,000 | +20.4% | 219,642 | -0.8% | 0.01% | +14.3% |
| Q2 2016 | $4,512,000 | +53.6% | 221,496 | +15.0% | 0.01% | +40.0% |
| Q1 2016 | $2,937,000 | +479.3% | 192,621 | +411.0% | 0.01% | +400.0% |
| Q4 2015 | $507,000 | -3.6% | 37,692 | +0.6% | 0.00% | 0.0% |
| Q3 2015 | $526,000 | +16.4% | 37,466 | +40.8% | 0.00% | 0.0% |
| Q2 2015 | $452,000 | – | 26,602 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |